Choongwae's Curoxin, new quinolone anti-bacterial drug, to launch soon.

Published: 2001-12-17 06:57:00

Updated: 2001-12-17 06:57:00

Choongwe (President: Lee Kyung-ha) announced on Dec. 13 that they may get the health registration approval for Curoxin (Balofloxacin), a new quinolone antibacterial agent from the KFDA on Dec. 17 through the Central Pharmaceutical Affairs Review Council after successful completion of the clinical...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK